Give each peptide its own shot: we found no study showing that any two research peptides are safe to mix in one syringe. Beyond the syringe, some pairs repeat one mechanism or pile risk onto one system, and this lesson names them.
Same receptor, twice
GHRP-6 and GHRP-2. Our sleep guide states it directly: avoid combining these, as they target the same receptor.
There is no additive benefit from occupying one receptor with two ligands. There is additive cost, additive injection burden, and additive unknowns. GHRP-6 gives the stronger GH release along with appetite stimulation and cortisol and prolactin spikes; GHRP-2 is the more selective of the two. Pick one.
Multiple GH-axis compounds
The Playbook's tesamorelin contraindications are explicit: do not combine with exogenous GH or other GH secretagogues such as CJC-1295 or ipamorelin without medical guidance, because stacking GH-axis compounds amplifies risks unpredictably.
The tesamorelin/ipamorelin pairing is described positively elsewhere in our material because the mechanisms genuinely differ. Both statements are true simultaneously. The pairing is mechanistically sensible and it is still two GH-axis compounds requiring IGF-1, glucose and lipid monitoring.
Adding a third, a GHRP on top or MK-677 on top, is where it stops being a considered decision.
Multiple growth-promoting peptides
Amplified angiogenesis and proliferation signals. The concern is cancer risk, and the mechanism is specific: BPC-157 upregulates VEGF, and other growth peptides may amplify this. For someone with cancer risk factors, that combination is the one to raise with a physician first.
Any peptide with CNS-active medication, without physician awareness
The Playbook lists this as a category, not a specific pairing.
DSIP is the clearest case. It affects GABA pathways, the same system benzodiazepines act on, and benzodiazepines, other CNS depressants and ACE inhibitors are all named contraindications. Selank is described in our material as acting on the same system, though we hold no dosing or interaction data for it.
But the rule is broader than DSIP: drug interactions with peptides are understudied across the board, and CNS-active medication is where the consequences of an unstudied interaction are least forgiving.
Two incretin agonists
Semaglutide, tirzepatide and retatrutide are all built on the GLP-1 mechanism. Tirzepatide adds GIP, retatrutide adds GIP and glucagon. Running more than one duplicates the shared pathway while multiplying the gastrointestinal burden and the class risks: MTC boxed warning, gallbladder events, lean mass loss, altered absorption of every oral medication.
These are prescription decisions in any case. The tirzepatide and semaglutide weight-reduction labels both advise against using either one with any other GLP-1 medicine. Retatrutide is still investigational and not approved.
Different peptides in the same syringe
A mechanical rule rather than a pharmacological one, but it belongs on the list. Two peptides means two shots.
We found no study that tested any two research peptides mixed in one syringe, so nobody knows what mixing does to either one. Two approved labels agree. When tirzepatide or semaglutide is used with insulin, their labels say the two go in as separate shots and are never mixed.
The worry is chemistry. A pharmacy review of mixing injectable drugs warns that one or both can lose their activity. A mix that looks unchanged can still have broken down. Problems are more likely in the small, concentrated volumes a syringe holds.
A blend vial is not proof that mixing is safe. Its seller mixed it, and we found no stability study for blends either.
What Claritide's safety checker flags
The safety checker in the app reads the compounds you run together. It flags four kinds of problem:
- Two compounds on one mechanism.
- A load piling up on one system, such as growth hormone or blood sugar.
- Known interactions with medicines.
- Label warnings, such as the thyroid tumor warning on GLP-1 medicines.
Every result carries the same line, whether or not anything was flagged: Absence from this list does NOT mean safety. It means lack of research. A clean result means nobody has studied the combination, not that it is safe.
The GHK-Cu topical exception, and why it is instructive
Layering GHK-Cu with strong AHAs, BHAs or pure L-ascorbic acid vitamin C breaks the copper-peptide bond and renders the product inert.
This is worth ending on because it is a different kind of "never combine". Nothing harmful happens. You simply waste the product, silently, while believing you are using it.
Not every incompatibility announces itself. Some of them just quietly make the last three months pointless, which is a reasonable summary of why this module exists.